CNTB reports positive preliminary topline data
CNTB said its global Phase 2 study of rademikibart produced positive preliminary topline data.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Connect Biopharma (CNTB) Reports Positive Phase 2 COPD Add-On Results
Connect Biopharma reported preliminary topline Phase 2 data showing rademikibart cut treatment failure by 81% (p=0.0122) and new moderate-to-severe COPD exacerbations by 85% (p=0.030) through one month; hospital/ED visits for new acute exacerbations were reduced by 100% (p=0.0137).Material DetailsC…